Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021

A. Brêchet, P. Kohler, T. Dörr, F. Grässli, M. Vock, J. Salát, D. Růžek, A. Friedl, D. Vuichard-Gysin, A. Croxatto, R. Lienhard, R. Ackermann-Gäumann

. 2025 ; 15 (1) : 8346. [pub] 20250311

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25009516

Grant support
PZ00P3_179919 Swiss National Sciences Foundation
NU21-05-00143 Ministerstvo Zdravotnictví Ceské Republiky
NU21-05-00143 Ministerstvo Zdravotnictví Ceské Republiky

Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconversions in unvaccinated individuals were confirmed by seroneutralization testing. Questionnaire data were used to determine vaccination status and risk factors. TBEV E protein-specific IgG prevalence was 72.1% (95% CI 68.2-75.7%) in TBEV-vaccinated and 6% (95% CI 4.4-7.8%) in unvaccinated individuals. The estimated annual incidence of infection was 735/100,000. Age was the only factor significantly associated with seroprevalence. The seroreversion rate in unvaccinated individuals was 30.3% within one year, which is almost ten times higher than in vaccinated individuals (3.4%, annual decline rate 8.0%). NS1-specific IgG antibodies were six times more common in vaccinated than unvaccinated HCWs. In conclusion, undetected TBEV infections are common, and infection incidence is much higher than reported clinical cases. Individuals with abortive infections have high antibody decline and seroreversion rates. Whether lifelong protection is conferred and by which immune subsets remain unclear.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009516
003      
CZ-PrNML
005      
20250430094621.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-025-92560-1 $2 doi
035    __
$a (PubMed)40069290
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Brêchet, Arthur $u Microbiologie, ADMED Analyses et Diagnostics Médicaux, La Chaux-de-Fonds, Switzerland
245    10
$a Tick-borne encephalitis virus seroprevalence and infection incidence in Switzerland, 2020-2021 / $c A. Brêchet, P. Kohler, T. Dörr, F. Grässli, M. Vock, J. Salát, D. Růžek, A. Friedl, D. Vuichard-Gysin, A. Croxatto, R. Lienhard, R. Ackermann-Gäumann
520    9_
$a Tick-borne encephalitis virus (TBEV) infection can manifest as disease of variable severity, ranging from subclinical infection to severe disease with neurological involvement and potentially fatal outcome. Although TBE is recognized as a major public health problem in Europe, the true burden of disease is potentially underestimated. Here, we investigated TBEV-specific antibody prevalence, infection incidence, and seroreversion and antibody decline rates in a prospective Swiss healthcare worker (HCW) cohort. We screened serum samples from 1444 HCWs between June and October 2020, and from a subset again between August and September 2021, using a TBEV envelope (E) protein IgG ELISA. Positive samples underwent further analysis with a TBEV non-structural protein 1 (NS1) IgG ELISA, and seroconversions in unvaccinated individuals were confirmed by seroneutralization testing. Questionnaire data were used to determine vaccination status and risk factors. TBEV E protein-specific IgG prevalence was 72.1% (95% CI 68.2-75.7%) in TBEV-vaccinated and 6% (95% CI 4.4-7.8%) in unvaccinated individuals. The estimated annual incidence of infection was 735/100,000. Age was the only factor significantly associated with seroprevalence. The seroreversion rate in unvaccinated individuals was 30.3% within one year, which is almost ten times higher than in vaccinated individuals (3.4%, annual decline rate 8.0%). NS1-specific IgG antibodies were six times more common in vaccinated than unvaccinated HCWs. In conclusion, undetected TBEV infections are common, and infection incidence is much higher than reported clinical cases. Individuals with abortive infections have high antibody decline and seroreversion rates. Whether lifelong protection is conferred and by which immune subsets remain unclear.
650    _2
$a lidé $7 D006801
650    12
$a viry klíšťové encefalitidy $x imunologie $7 D004669
650    12
$a klíšťová encefalitida $x epidemiologie $x imunologie $x krev $7 D004675
650    _2
$a séroepidemiologické studie $7 D016036
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a protilátky virové $x krev $7 D000914
650    _2
$a imunoglobulin G $x krev $7 D007074
650    _2
$a prospektivní studie $7 D011446
650    _2
$a zdravotnický personál $x statistika a číselné údaje $7 D006282
650    _2
$a senioři $7 D000368
651    _2
$a Švýcarsko $x epidemiologie $7 D013557
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kohler, Philipp $u Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
700    1_
$a Dörr, Tamara $u Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
700    1_
$a Grässli, Fabian $u Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
700    1_
$a Vock, Michael $u Institute of Mathematical Statistics and Actuarial Science, University of Bern, Bern, Switzerland
700    1_
$a Salát, Jiří $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Brno, Czech Republic $u Laboratory of Arbovirology, Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Růžek, Daniel, $d 1981- $u Laboratory of Emerging Viral Infections, Veterinary Research Institute, Brno, Czech Republic $u Laboratory of Arbovirology, Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 stk2008441707
700    1_
$a Friedl, Andrée $u Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital Baden, Baden, Switzerland
700    1_
$a Vuichard-Gysin, Danielle $u Thurgau Hospital Group, Division of Infectious Diseases and Hospital Epidemiology, Muensterlingen, Switzerland
700    1_
$a Croxatto, Antony $u Microbiologie, ADMED Analyses et Diagnostics Médicaux, La Chaux-de-Fonds, Switzerland $u Swiss National Reference Center for Tick-Transmitted Diseases, Lausanne, Switzerland
700    1_
$a Lienhard, Reto $u Microbiologie, ADMED Analyses et Diagnostics Médicaux, La Chaux-de-Fonds, Switzerland $u Swiss National Reference Center for Tick-Transmitted Diseases, Lausanne, Switzerland
700    1_
$a Ackermann-Gäumann, Rahel $u Microbiologie, ADMED Analyses et Diagnostics Médicaux, La Chaux-de-Fonds, Switzerland. rahel.ackermann@itransfusion.ch $u Swiss National Reference Center for Tick-Transmitted Diseases, Lausanne, Switzerland. rahel.ackermann@itransfusion.ch $u Interregional Blood Transfusion SRC, Bern, Switzerland. rahel.ackermann@itransfusion.ch
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 15, č. 1 (2025), s. 8346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40069290 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250430094616 $b ABA008
999    __
$a ok $b bmc $g 2311104 $s 1246597
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 1 $d 8346 $e 20250311 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a PZ00P3_179919 $p Swiss National Sciences Foundation
GRA    __
$a NU21-05-00143 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NU21-05-00143 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options